Muhammad Idrees

Muhammad Idrees

Auto-generated profile, based on publicly available information

Muhammad Idrees

Center of Excellence in Molecular Biology (CEMB), University of the Punjab, Lahore, Pakistan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2018 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
BWBraira Wahid
Braira Wahid
MWMuhammad Waqar
Muhammad Waqar
NRNouman Rasool
Nouman Rasool
MWMuhammad Wasim
Muhammad Wasim
IKIfrah Khalid
Ifrah Khalid
MIMuhammad Idrees
Muhammad Idrees

17 May 2020 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
BWBraira Wahid
Braira Wahid
KSKhadija Shami
Khadija Shami
SJSalman A. Joiya
Salman A. Joiya
SÖSevilay Ece Gümüş Özuyar
Sevilay Ece Gümüş Özuyar
MIMuhammad Idrees
Muhammad Idrees

11 January 2021 in Future Virology
Verified
Journal Article
Closed access
AAAyma Aftab
Ayma Aftab
SASamia Afzal
Samia Afzal
MIMuhammad Idrees
Muhammad Idrees
ASAhmad Ali Shahid
Ahmad Ali Shahid
Aim: To identify methylation in p53 and rb during hepatitis C virus (HCV) infection in individuals in Pakistan. Materials & methods: Methylation-specific PCR was used on liver biopsies from hepatoc...

29 October 2024 in F1000Research
Verified
Journal Article
Open access
PDF file
RNRabia Nawaz
Rabia Nawaz
AHAli Husnain
Ali Husnain
MAMuhammad Ali Arif
Muhammad Ali Arif
ZHZohal Hassan
Zohal Hassan
AAAmmara Ahad
Ammara Ahad
Wayne CarterWayne Carter
Wayne Carter
Background Antibiotic misuse and overuse have contributed to the emergence of multi-drug resistant (MDR) bacteria, posing a serious public health problem across the globe. Phage cocktails, which combine multiple phages, provide an efficient method to combat multidrug-resistant bacterial infections. This study integrated a computational pipeline to design a phage cocktail against the bacterial strains Acinetobacter baumannii AB0057, Klebsiella pneumoniae subsp. pneumoniae HS11286, and Pseudomonas aeruginosa UCBPP-PA14. Methods The whole genome sequences of selected multidrug-resistant bacteria were accessed. Prophage sequences were identified from them which could be expressed to produce viable lytic phages against MDR bacterial strains, thereby reducing the severity of infection. Prophages were annotated for open reading frames (ORFs), putative promoters, virulence factors, transcriptional terminators, ribosomal RNAs, and transfer RNAs. A dot plot was also generated to investigate similar phages and phylogenetic analysis was performed. Results A total of 11 prophages were predicted from the bacterial genomes. About 472 open reading frames were predicted along with 3 transfer RNAs. Additionally, the presence of 754 putative promoters and 281 transcription terminator sequences was also detected. Comparative genomic and phylogenetic analyses provided insight into the diversity, relatedness, and lytic potential of the phages. The final designed phage cocktail consisted of five selected prophages including Acinetobacter baumannii prophages (2759376-2809756) and (3311844-3364667), and Klebsiella pneumoniae prophages (1288317-1338719), (1778306-1808606), and (2280703-2325555). Conclusion The phage cocktail designed in this study might be useful against MDR Acinetobacter baumannii and Klebsiella pneumoniae infections, especially where conventional antibiotics fail. Sequence similarity analysis suggested that the phage cocktail may also be effective against other carbapenemase-producing K. pneumoniae strains.

1 December 2023 in Experimental Biology and Medicine
Verified
Journal Article
Open access
SMSadia Minhas
Sadia Minhas
MKMuhammad Kashif
Muhammad Kashif
HNHaseeb Nisar
Haseeb Nisar
MIMuhammad Idrees
Muhammad Idrees
FAFarheen Ansari
Farheen Ansari
High-throughput genome-wide sequencing has revealed high genomic variability of HPV16 in different geographic regions which is the most predominant genotype in human papillomavirus (HPV)–associated malignancies. Analysis of the HPV16 by whole-genome sequence (WGS) is an advanced method for the identification of mutations in the genome. There is limited information about HPV16 diversity in Pakistan, especially at the genomic level. Till now, WGS for HPV16 has not been previously reported in Pakistan. The current study has sequenced three HPV16 viral genomes, from two cervical and one oral cavity positive sample of women presented with general gynecological problems without any evidence of precancerous or cancerous lesions using an ion ampliseq customized panel. Sequencing analysis detected 38 variations, including single-nucleotide polymorphisms (SNPs) and two Indels, across three samples with the highest number of SNPs present in E1, E2, and L2, respectively. A total of 20 non-synonymous and 11 synonymous mutations with amino acid substitutions (T1421C, G1515A, T2223C, T1389C, G1483A, and T2191C) were identified. The phylogenetic analysis revealed the genomes of HPV16 are closely associated with those reported from Thailand and the United States. These are the first HPV16 WGS from Pakistan. However, more research is needed with a large sample size from diversified areas to assess the carcinogenic consequences and impact of HPV vaccinations.

30 April 2022 in Osong Public Health and Research Perspectives
Verified
Journal Article
Open access
IMIqra Mir
Iqra Mir
SASania Aamir
Sania Aamir
SSSyed Rizwan Hussain Shah
Syed Rizwan Hussain Shah
MSMuhammad Shahid
Muhammad Shahid
IAIram Amin
Iram Amin
MIMuhammad Idrees
Muhammad Idrees
The coronavirus disease 2019 (COVID-19) pandemic rapidly spread globally. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19, is a positive-sense single-stranded RNA virus with a reported fatality rate ranging from 1% to 7%, and people with immune-compromised conditions, children, and older adults are particularly vulnerable. Respiratory failure and cytokine storm-induced multiple organ failure are the major causes of death. This article highlights the innate and adaptive immune mechanisms of host cells activated in response to SARS-CoV-2 infection and possible therapeutic approaches against COVID-19. Some potential drugs proven to be effective for other viral diseases are under clinical trials now for use against COVID-19. Examples include inhibitors of RNA-dependent RNA polymerase (remdesivir, favipiravir, ribavirin), viral protein synthesis (ivermectin, lopinavir/ritonavir), and fusion of the viral membrane with host cells (chloroquine, hydroxychloroquine, nitazoxanide, and umifenovir). This article also presents the intellectual groundwork for the ongoing development of vaccines in preclinical and clinical trials, explaining potential candidates (live attenuated-whole virus vaccines, inactivated vaccines, subunit vaccines, DNA-based vaccines, protein-based vaccines, nanoparticle-based vaccines, virus-like particles and mRNA-based vaccines). Designing and developing an effective vaccine (both prophylactic and therapeutic) would be a long-term solution and the most effective way to eliminate the COVID-19 pandemic.